BRCA2 and breast carcinoma: For the example of female breast cancer, individuals in the top 0.3% of the breast cancer Enhanced PRS distribution have an equivalent average lifetime risk to deleterious mutation carriers for BRCA1 or BRCA2 genes in UK Biobank (35% to age 70, S8A Fig).